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Abstract
Introduction Daily interruption of sedation (DIS) and sedation
algorithms (SAs) have been shown to decrease mechanical
ventilation (MV) duration. We conducted a randomized study
comparing these strategies.
Methods Mechanically ventilated adults 18 years old or older in
the medical intensive care unit (ICU) were randomly assigned to
DIS or SA. Exclusion criteria were severe neurocognitive
dysfunction, administration of neuromuscular blockers, and
tracheostomy. Study endpoints were total MV duration and 28-
day ventilator-free survival.
Results The study was terminated prematurely after 74 patients
were enrolled (DIS 36 and SA 38). The two groups had similar
age, gender, racial distribution, Acute Physiology and Chronic
Health Evaluation II score, and reason for MV. The Data Safety
Monitoring Board convened after DIS patients were found to
have higher hospital mortality; however, no causal connection
between DIS and increased mortality was identified. Interim
analysis demonstrated a significant difference in primary
endpoint, and study termination was recommended. The DIS
group had longer total duration of MV (median 6.7 versus 3.9
days; P = 0.0003), slower improvement of Sequential Organ
Failure Assessment over time (0.70 versus 0.23 units per day; P
= 0.025), longer ICU length of stay (15 versus 8 days; P <
0.0001), and longer hospital length of stay (23 versus 12 days;
P = 0.01).
Conclusion In our cohort of patients, the use of SA was
associated with reduced duration of MV and lengths of stay
compared with DIS. Based on these results, DIS may not be
appropriate in all mechanically ventilated patients.
Trial registration ClinicalTrials.gov NCT00205517.
Introduction
The method of sedation administration has been shown to
impact duration of mechanical ventilation (MV) in critically ill
patients. Daily interruption of sedation (DIS) has been shown
to decrease duration of MV [1,2]. While some studies examin-
ing the effectiveness of sedation algorithms (SAs) have found
a decrease in duration of MV by 2.6 to 5.9 days, others have
found no difference, although these latter trials were not rand-
omized [3-6]. Additionally, DIS appears to be protective
against the development of further organ dysfunction, while
studies examining SA found neither a worsening nor an
improvement of organ dysfunction [3,4,7]. Both DIS and SA
have been associated with decreased administration of seda-
tives and opioids [1,4].
Studies examining DIS and SA have compared these strate-
gies to conventional care or modifications of the initial strategy
[8]. In the recently published Awakening and Breathing Con-
ABC = Awakening and Breathing Controlled; ANOVA = analysis of variance; APACHE = Acute Physiology and Chronic Health Evaluation, CI = con-
fidence interval; DIS = daily interruption of sedation; DSMB = Data Safety Monitoring Board; ICU = intensive care unit; IQR = interquartile range, IRB 
= Institutional Review Board; MV = mechanical ventilation; RASS = Richmond Agitation-Sedation Scale; SA = sedation algorithm; SBT = spontane-
ous breathing trial; SOFA = Sequential Organ Failure Assessment.
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trolled (ABC) trial, both groups were managed with a sponta-
neous breathing trial (SBT) and one group was also managed
with a modified DIS protocol in which analgesics could be
continued if deemed necessary for pain [2]. In both arms of the
study, patients could be managed by an SA, but this was not
mandated. To our knowledge, no study has directly compared
DIS with SA. We therefore designed a randomized study com-
paring DIS and SA.
Materials and methods
The study was conducted in accordance with the ethical
standards of the Virginia Commonwealth University Institu-
tional Review Board (IRB) and the Declaration of Helsinki, and
the study was performed at Virginia Commonwealth University
Medical Center (Richmond, VA, USA). The IRB approved the
study, and written consent was obtained. Adults 18 years old
or older receiving invasive MV in the closed medical intensive
care unit (ICU) were eligible for study participation unless they
met exclusion criteria. Exclusion criteria were neuromuscular
blockade, severe chronic neurocognitive dysfunction requiring
assistance with most activities of daily living, transfer from
another ICU, tracheostomy at the time of study enrollment, or
inability to obtain consent before the time point when sedation
was to be interrupted.
Patients were randomly assigned to one of two sedation strat-
egies: DIS or nursing-implemented SA. Sedation in all patients
was managed according to the algorithm up to the time of ran-
domization. The SA was developed locally by the medical ICU
physicians, pharmacist, and nursing staff and was based on
the algorithm developed by Brook and colleagues [3] and on
Society of Critical Care Medicine guidelines [9]. The algorithm
goals were to maximize the use of boluses, minimize the dura-
tion of continuous intravenous infusion of sedation, and treat
pain with opioids (Figure 1). It included daily attempts to
decrease sedation dosages. The Richmond Agitation-Seda-
tion Scale (RASS) was used to measure sedation level, and
sedation was titrated to a goal RASS score of -2 to -3 unless
otherwise specified by the ICU team (Table 1) [10]. The ICU
nursing staff underwent a 2-month introductory period in the
use of the algorithm. After educational training, the algorithm
underwent a 1-month run-in period prior to study initiation.
During the trial, nurses assigned to study patients were asked
daily whether they required any clarification regarding the
algorithm. Nurses administered sedatives and opiates as man-
dated by the algorithm. Study investigators monitored compli-
ance with the algorithm by evaluating sedation levels in
patients randomly assigned to SA on two occasions per day,
with the timing of the events being at the discretion of investi-
gators and separated by at least 2 hours.
DIS was performed initially would leave initially out as outlined
by Kress and colleagues [1]. Forty-eight hours after initiation
of MV, all sedatives and opioids administered as either contin-
uous infusions or bolus infusions were discontinued until the
patient was awake or agitated. Sedation was typically inter-
rupted in the morning, but timing was based on practicalities
such as daily rounds, procedures, and travel outside the ICU.
Patients were observed continuously by a study investigator
(MdW or WIJ) during sedative and opioid interruption. Awake
was defined as being able to perform at least three of the fol-
lowing four commands: (a) open eyes, (b) visually track the
investigator, (c) stick out tongue, and (d) squeeze hand [1].
Agitation was defined a priori as an RASS score of greater
than 0. Study investigators decided if and when to resume
sedation. Patients randomly assigned to DIS were not man-
aged with the SA, and all sedation management was left to the
discretion of the ICU team. However, clinicians were
instructed to target an RASS score of -2 to -3 unless the ICU
team felt that a different sedation depth was necessary. Clini-
cians titrated sedatives and opioids throughout the day when
study investigators were not present. Patients treated by DIS
had sedation levels recorded at the time sedation was inter-
rupted and again when sedation was resumed. Clinicians
involved in the care of study patients did not initiate sedation
interruption, nor were they involved in the decision to resume
sedation.
After the third patient randomly assigned to DIS experienced
a study-related adverse event, the DIS protocol was amended
because of safety concerns. During sedation interruption, the
patient developed hypertension and subsequent tachycardia,
tachypnea, and patient-ventilator asynchrony. Treatment with
sedatives led to resolution of the hypertension and tachycar-
dia, but the tachypnea and patient-ventilator asynchrony per-
sisted and necessitated the administration of a
neuromuscular-blocking agent. The protocol was amended to
resume sedation if any of the following vital sign changes
occurred: tachypnea of greater than 35 breaths per minute for
more than 5 minutes, arterial oxygen saturation of less than
90%, heart rate of greater than 140 beats per minute or sus-
tained change of greater than 20% in either direction, or systo-
lic blood pressure of greater than 180 mm Hg or less than 90
mm Hg. These changes were based on a study evaluating the
efficacy of SBTs [11]. Once a patient was awake, agitated, or
developed vital sign changes, sedation was resumed at half
the previous dose. Boluses could be administered if deemed
necessary to treat agitation or vital sign changes. MV weaning
was standardized in both groups through the use of daily
SBTs [11].
Data analysis
The purpose of the study was to compare the time to a suc-
cessful extubation in the two groups. The time to successful
extubation was compared using a Kaplan-Meier survival analy-
sis. The subjects in the two randomly assigned groups were
analyzed using the intent-to-treat principle. Statistical signifi-
cance was determined using a log-rank test. This statistical
test allowed for the fact that not all patients achieved a suc-
cessful extubation. That is, all subjects were included in the
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analysis even if they did not have a successful extubation.
Unsuccessful extubations created censored observations.
Censoring occurred if a patient died on MV, withdrew from the
study, required reintubation (within 72 hours of extubation), or
underwent tracheostomy. We chose to censor for reintubation
and tracheostomy because these events have been shown to
be affected by sedation method.
We also computed 28-day ventilator-free survival, which is
defined as the number of days within the first 28 days after
enrollment during which the patient was alive and breathing
without assistance, if the period of unassisted breathing was
72 hours or longer [12]. Finally, we computed the total dura-
tion of MV, which was calculated as the time from randomiza-
tion until extubation. This included time after reintubation,
tracheostomy, or MV up to 28 days after enrollment [13].
One interim analysis was scheduled when half the targeted
number of patients were enrolled. The trial was set to be halted
at interim analysis if the P value was less than alpha and alpha
= 0.001. For the remainder of the analyses, alpha was set to
0.05. However, after a patient experienced complications dur-
ing sedation interruption, the Data Safety Monitoring Board
(DSMB) chose to closely follow all reported adverse events
and perform an interim analysis as necessary based on clinical
expertise and safety concerns. Investigators submitted all pre-
defined adverse events to the DSMB within 2 business days;
these events were unplanned extubation, reintubation, hospital
mortality, and an RASS score of greater than 2. The DSMB
performed one interim analysis when investigators noted that
patients randomly assigned to DIS had higher mortality.
Sedation levels were compared using mixed-model repeated
measures analysis of variance (ANOVA; for RASS variable) or
a generalized estimating equation (for the awake variable)
Figure 1
The sedation algorithm used in this study. gtt, drop; MRICU, medical respiratory intensive care unit; prn, as necessary (pro re nata); q, every; qd, 
each day (quaque die); RASS, Richmond Agitation-Sedation Scale.
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model [14]. The total dose of sedatives and opioids was
recorded and converted to midazolam and fentanyl equiva-
lents using referenced conversion formulas [15,16]. Medica-
tion doses were compared using the Wilcoxon rank sum test.
A mixed-effects ANOVA was used to model severity of illness
using the Sequential Organ Failure Assessment (SOFA) over
time [17]. Hospital and ICU lengths of stay were compared by
log-rank with censoring for study withdrawal. Other variables
collected included age, race, severity of illness as measured
by Acute Physiology and Chronic Health Evaluation II
(APACHE II), and MV reason [18]. Normally distributed data
are reported as mean and 95% confidence interval (CI). Non-
normally distributed data are reported as median and inter-
quartile range or as median and 95% CI.
Power calculation
Brook and colleagues [3] observed a median time on MV to be
2.3 days in the SA group compared with 4.9 days for the con-
trol group. Kress and colleagues [1] observed median times of
4.9 days in the DIS group and 7.3 days for the control group.
A priori, a meaningful difference between the two groups was
set at 2 days. With a censoring rate of 13%, 268 patients were
deemed necessary to detect a significant difference between
groups using a log-rank test with 80% power and a two-sided
test.
Results
Seventy-five patients were enrolled. One patient withdrew
immediately after randomization (DIS group). Baseline charac-
teristics of 74 patients revealed no difference in age, gender
distribution, racial composition, severity of illness, and reason
for MV (Table 2). At study entry, DIS and SA patients had sim-
ilar RASS scores, were equally likely to be awake, and had
received similar doses of sedatives and opioids. Interim analy-
sis was performed early because of safety concerns and
revealed increased hospital mortality in patients treated by
DIS. Because the study primary endpoint might affect mortal-
ity, the DSMB reviewed this. The study was designed a priori
to detect a 2-day difference in MV duration, and the DSMB
recommended study termination after this endpoint was
reached. It should be noted that investigators were not mem-
bers of the DSMB and were not involved in the DSMB's data
analysis. The study was not terminated because of the finding
of increased hospital mortality in patients treated by DIS.
Censoring
Thirty-six patients were censored. Patients randomly assigned
to DIS were significantly more likely to have censored obser-
vations (DIS 24 versus SA 12; P = 0.004). Reasons for cen-
soring included reintubation (DIS 8 and SA 5), death on MV or
medical treatment withdrawn (DIS 8 and SA 6), tracheostomy
(DIS 2 and SA 0), and study withdrawal (DIS 6 and SA 1).
Patients randomly assigned to DIS were more likely to with-
draw from the study (P = 0.03). Five patients (4 DIS and 1 SA)
were withdrawn at the request of the legally authorized repre-
sentative because of concerns that patients were insufficiently
sedated. Two patients randomly assigned to DIS were with-
drawn at the request of the attending physician because the
patients were not felt to be appropriate candidates for DIS.
(The first patient was the subject who developed the adverse
events described above, and the second subject was a patient
with acute fulminant liver failure with a concern for increased
intracranial pressure.)
Mechanical ventilation and length of stay
The time to successful extubation from MV was 4.0 days
longer in the DIS group (median 8.1 days, 95% CI 4.1, unde-
terminable days for DIS versus 4.1 days, 95% CI 3.0, 4.9 days
for SA). The total duration of MV was 2.8 days longer for the
DIS group (Table 3). A Kaplan-Meier analysis graphing the
total duration of MV shows that the probability of remaining on
MV was reduced in the SA group (Figure 2). The 28-day ven-
Table 1
Richmond Agitation-Sedation Scale
Score Term Description
+4 Combative Overtly combative or violent and an immediate danger to staff
+3 Very agitated Pulls on or removes tube(s) or catheter(s) or has aggressive behavior toward staff
+2 Agitated Frequent nonpurposeful movement or patient ventilator dyssynchrony
+1 Restless Anxious or apprehensive but movements not aggressive or vigorous
0 Alert and calm
-1 Drowsy Not fully alert but has sustained (> 10 seconds) awakenings, with eye contact, to voice
-2 Light sedation Briefly (< 10 seconds) awakens with eye contact to voice
-3 Moderate sedation Any movement (but no eye contact) to voice
-4 Deep sedation No response to voice, but any movement to physical stimuli
-5 Unarousable No response to voice or physical stimulation
Available online http://ccforum.com/content/12/3/R70
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tilator-free survival was 7 days longer in the SA group com-
pared with the DIS group (P = 0.004) (Table 3). Both the ICU
and hospital lengths of stay were longer for DIS patients
(Table 3).
Sedation
A total of 671 RASS evaluations were performed (DIS 413
and SA 258). RASS score increased over time in both groups
(P = 0.02), and the increases were similar for the two groups.
However, DIS patients consistently had higher RASS values
(0.6 units) than SA patients (Figure 3). The probability of being
awake (as defined by Kress and colleagues [1]) did not
change over time (P = 0.53), and there was no difference
between the two groups (P = 0.78). Patients were awake on
46% of evaluations. Patients treated by DIS were agitated
(RASS score > 0) during 18% of the evaluations, whereas
patients treated by SA were agitated on 5% of the evaluations
(P < 0.0001). There was no difference in the amount of seda-
tives and opioids administered between the two groups (Table
3).
Sedation interruption
In the DIS group, assessments were made for sedation inter-
ruption on 173 occasions. In 92% of the cases, patients were
receiving continuous infusions; in 4% of the cases, patients
were receiving boluses; in the remaining 4% of the cases,
patients were not receiving sedation as it had been held from
the previous day. On 94 occasions, patients were either
awake (as defined by Kress and colleagues [1] on 89 occa-
sions) or agitated (RASS score > 0 on 5 occasions) and did
not require sedation interruption. On the 79 occasions when
sedation was interrupted, sedation was interrupted for a mean
of 3.5 hours (95% CI 2.61, 4.37 hours). Patients subsequently
met the definition of awake on 22 occasions (12 occasions
without agitation or vital sign changes and 10 occasions with
both agitation and vital sign changes). On 47 occasions,
patients developed agitation and were not awake; on 25 occa-
sions, patients developed vital sign changes (in 8 out of 33
patients who were enrolled in the modified protocol). Extreme
tachypnea at a mean rate of 51 breaths per minute as meas-
ured on the ventilator (95% CI 45.0, 57.3 breaths per minute)
was the reason for sedation resumption in 22 out of 25
occasions.
Severity of illness
SOFA decreased throughout the study in both groups (P <
0.001). However, the SA group had a more rapid improvement
in SOFA: 0.70 units per day in the SA group compared with
0.23 units per day in the DIS group (P = 0.025) (Figure 4).
Mortality
Thirteen patients treated by DIS died in hospital compared
with 7 treated by SA (P = 0.04, analysis excluded patients
who withdrew from the study). Eight patients treated by DIS
Table 2
Baseline characteristics for patients randomly assigned to daily interruption of sedation (DIS) and sedation algorithm (SA)
DIS n = 36 SA n = 38 P value
Age in years, mean (95% CI) 52 (47.4, 56.5) 51 (46.8, 55.8) 0.84
Gender, female 19 20 0.99
Race, African-American/white/other 18/17/1 20/17/1 0.97
Reason for mechanical ventilation 0.52
Pneumonia/Acute lung injury 17 14
Sepsis 6 5
Delirium/neurologic 5 6
Cardiac 2 6
Asthma/Chronic obstructive pulmonary disease 1 2
Other 5 5
APACHE II score 26 (22.9, 28.8) 24 (21.6, 27.4) 0.52
Sequential Organ Failure Assessment score 10 (8.2, 10.9) 9 (7.6, 10.3) 0.50
Midazolam equivalents before randomization in mg/kg, median (IQR) 0.5 (0.05, 2.61) 0.6 (0.0, 3.73) 0.81
Fentanyl equivalents before randomization in μg/kg, median (IQR) 0.4 (0.0, 2.93) 0.8 (0.0, 2.27) 0.52
Propofol before randomization in μg/kg, median (IQR) 90 (0, 29,625) 0 (0, 49,956) 0.79
Awake, number 13 14 0.95
Richmond Agitation-Sedation Scale score, mean (95% CI) -3 (-3.4, -2.3) -3 (-3.0, -2.0) 0.37
APACHE II, Acute Physiology and Chronic Health Evaluation II; CI, confidence interval; IQR, interquartile range.
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died in the ICU compared with 5 treated by SA (P = 0.20,
excluding participants who withdrew). The DSMB reviewed
the causes of mortality and could not determine a common eti-
ology. In particular, 8 patients randomly assigned to DIS who
died had progressive deterioration and subsequently had care
withdrawn at the recommendation of the medical team. Three
of 5 patients randomly assigned to SA who died had care with-
drawn; in 2 cases, this was at the recommendation of the
medical team and in 1 case at the request of the patient's next
of kin.
Discussion
The main findings from our study are the following: compared
with DIS, the use of an SA was associated with (a) decreased
duration of MV, (b) more rapid resolution of critical illness, and
(c) shorter ICU and hospital lengths of stay. (d) Additionally,
DIS was associated with less deep sedation levels but was not
associated with the administration of less sedative medication
compared with the use of SA.
Early in the study, a patient developed serious study-related
adverse events. When an interim analysis demonstrated
increased mortality rates in the DIS group, the DSMB, guided
by safety concerns, examined the primary endpoint as this
could potentially explain the mortality findings. When it was
noted that the a priori-defined difference in time to successful
extubation across the two groups exceeded 2 days, the
DSMB recommended study termination. It should be noted
that the study was not terminated because of the mortality
findings.
More patients treated by DIS were withdrawn from the study.
After study withdrawal, these patients were treated using the
ICU SA. This could have resulted in eliminating differences in
total MV duration between the two groups. However, the DIS
group had a longer total MV duration by 2.8 days (P =
0.0003), suggesting a true effect of DIS on MV outcome. Ven-
tilator-free survival was also improved by 7 days in the SA
group, although this did not reach significance (P = 0.004,
which is greater than the preset alpha of 0.001 for interim
analysis).
DIS has been advocated by the Surviving Sepsis Campaign
[19] and the Institute for Healthcare Improvement [20] as a
tool to improve patient outcome. Kress and colleagues [21]
previously demonstrated that use of DIS shortens the duration
of MV, decreases sedative administration, increases fre-
quency of wakefulness from 9% to 86%, and decreases the
frequency of neurodiagnostic testing. The recent ABC trial
also found that sedation interruption, when combined with an
SBT, resulted in improved ventilator-free survival [2]. Our
study differs significantly from that of Kress and colleagues
[21] and the ABC trial in a number of ways. First, we compared
DIS with a carefully implemented nurse-driven SA rather than
with a non-algorithmic approach. Although some patients in
the ABC trial may have been treated by an algorithm, this was
not a requirement. Second, the majority of our patients were
women and half of patients were African-American. Racial and
gender differences in medication metabolism are well
described, and studies have found that patient characteristics
influence medication benefit [22-25]. Third, in the ABC trial,
clinicians could continue the use of analgesics if they felt this
was necessary, and this occurred in 15% of patients whose
sedatives were discontinued [2]. Additionally, if patients
required escalating doses of sedatives, they were not consid-
ered candidates for sedation interruption. Our protocol was
modeled after that of Kress and colleagues [21]. In our proto-
col, escalating doses of sedatives did not preclude the discon-
tinuation of sedative and opioid medications unless a patient
was agitated at the time the medications were due to be
interrupted.
Although DIS patients had higher RASS scores, they did not
receive less sedation than the comparison group, an observa-
tion that may result from several factors. It is conceivable that
the SA used in our study resulted in more medication adminis-
tration than the control group in the study of Kress and col-
leagues. Alternatively, our DIS group may have received more
sedation because of the protocol modification requiring seda-
tion resumption because of changes in vital signs. Indeed, in a
third of occasions, sedation was resumed because of vital sign
criteria. Finally, it is also possible that the higher rates of agita-
tion in the DIS group resulted in an increased need for larger
doses of sedation, thereby eliminating dosage differences
between the two groups.
Another possibility is that our patient population contained a
high proportion of patients with alcohol and other drug use
disorders. In Richmond, the prevalence of these disorders is
18%, approximately twice the national rate, and our institution
Figure 2
Kaplan-Meier survival curve of total duration of mechanical ventilation (MV) for patients tre ted by daily interrupti  f sedation (thick line) a d sedati n algori hm (thin lin ) (P = 0.0003)
(MV) for patients treated by daily interruption of sedation (thick line) and 
sedation algorithm (thin line) (P = 0.0003).
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cares for many patients with these disorders [26,27]. In a
retrospective study, we found that 39% of our mechanically
ventilated critically ill patients have alcohol and other drug use
disorders, and this rate likely under-represents the true rate
due to the retrospective nature of the study [28]. Additionally,
alcohol and other drug use disorders typically are coexisting
diagnoses in our patients and are not usually the primary rea-
son for requiring MV. The prevalence of alcohol and other drug
use disorders in our medical ICU patients is likely to be sub-
stantially higher than in the study of Kress and colleagues and
the ABC trial. Neither of these two studies reported rates of
coexisting alcohol and other drug use disorders. Although one
patient in the study of Kress and colleagues required MV for a
drug overdose, the ABC trial reported that only 1% of patients
with alcohol withdrawal were enrolled in the study.
Alcohol withdrawal has been shown to be associated with
longer duration of MV, and patients with alcohol use disorders
can develop withdrawal syndromes if they are undersedated
or have early withdrawal of sedation [29,30]. Additionally, sed-
ative agents have been found to reduce the duration of alcohol
withdrawal delirium, and opioids have been shown to
decrease the stress response in critically ill patients with alco-
hol use disorders [31,32]. Patients with alcohol and other drug
use disorders require a 2.5-fold increase in dosage administra-
tion of sedatives and a 5-fold increase in opioid dosage admin-
istration to achieve sedation levels similar to patients without
these disorders [28]. It is possible that patients with alcohol
and other drug use disorders may well be patients who require
escalating doses of sedatives and opioids and who would not
have had their sedation interrupted in the ABC trial. Addition-
ally, it is possible that patients with these disorders did not
have their analgesic medications discontinued in the ABC trial,
thereby resulting in a blunted stress response during sedation
interruption and minimizing the symptoms of withdrawal during
sedation interruption [32]. The assessment of withdrawal syn-
dromes rests principally on patient self-reporting of subjective
sensations of irritability, nausea, headache, and tactile, visual,
and auditory hallucinations. No objective criteria exist for
assessing withdrawal in the non-verbal mechanically ventilated
ICU patient [33]. We believe the hypertension, tachycardia,
and tachypnea (that is, 'autonomic agitation') experienced by
the third patient randomly assigned to DIS may be explained
by withdrawal symptoms.
Based on the results of our study, DIS may not be the sedation
strategy of choice in all mechanically ventilated patients. We
cannot be sure that the sedative strategy alone was responsi-
Table 3
Comparison of outcome between daily interruption of sedation and sedation algorithm
Daily interruption of sedation n = 36 Sedation algorithm n = 38 P value
Median 95% CI Median 95% CI
Total duration of mechanical ventilation, days 6.7 4.1, 10.4 3.9 2.9, 4.9 0.0003
Intensive care unit length of stay, days 15 9.1, 21.2 8 6.5, 8.7 < 0.0001
Hospital length of stay, days 23 14.8, 28.7 12 11.3, 16.0 0.01
Median IQR Median IQR
28-day ventilator-free survival 16.1 0.00, 21.77 23.1 19.16, 25.06 0.004
Midazolam equivalents, mg/kg-day 0.2 0.01, 1.48 0.4 0.01, 1.32 0.70
Fentanyl equivalents, μg/kg-day 0.5 0.09, 2.43 1.2 0.12, 2.44 0.36
Propofol, μg/kg-day 0 0.0, 5817.0 0 0.0, 6589.0 0.39
CI, confidence interval; IQR, interquartile range.
Figure 3
Mixed-model repeated measures comparison of Richmond Agitation-Sedation Scal  (RASS) score over the course of mechanical ventilation in patients treated by daily interruption of edation (solid line) a d seda-tion lgorithm (dash line)
Sedation Scale (RASS) score over the course of mechanical ventilation 
in patients treated by daily interruption of sedation (solid line) and seda-
tion algorithm (dashed line). The group treated by daily interruption of 
sedation had higher RASS scores (P = 0.049). Individual measure-
ments are shown (× for sedation algorithm and é for daily interruption of 
sedation).
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ble for the difference in outcome as there are many uncon-
trolled factors (that is, comorbidities, severity of illness, organ
failure, and so on) and temporally some patients died after
leaving the ICU. However, our study raises some concerns
about the applicability of DIS in all patients and highlights the
need for additional randomized control trials. Previous trials
examining DIS were done at institutions with expertise in seda-
tion research and with a research coordinator at the bedside,
which may limit generalizabiltity.
Conclusion
In summary, in our cohort of patients, we found an SA to be
superior to DIS in decreasing the duration of MV. DIS may not
be effective in all patient populations and may potentially be
harmful in some patient groups. This study raises the question
of whether those with alcohol and other drug use disorders are
one such population. Evaluation of sedation interruption in
patients with alcohol and other drug use disorders requires
further study.
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